首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1735691

全球樹突細胞癌症疫苗市場規模（按產品類型、最終用戶、區域範圍）預測（至 2025 年）

Global Dendritic Cell Cancer Vaccine Market Size By Product Type (Sipuleucel-T, CreaVax), By End-User (Pediatric, Adults), By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

樹突細胞癌症疫苗市場規模及預測

預計2024年樹突狀細胞癌疫苗市場規模將達到24.1億美元，到2032年將達到51.8億美元，2026年至2032年的複合年成長率為10.5%。

樹突狀細胞幫助免疫系統辨識並清除異常細胞，包括癌細胞。為了研發疫苗，科學家在實驗室中將樹突細胞與癌細胞一起培養，以刺激人體免疫系統對抗惡性腫瘤。
II 期研究表明，樹突狀細胞免疫增加了浸潤腫瘤的淋巴細胞數量，引發了免疫反應，並可能提高某些患者的整體存活率。
此疫苗利用BETA細胞蛋白和患者自身的免疫細胞（樹突狀細胞）。透過指示免疫系統攻擊BETA細胞，疫苗可能有助於BETA細胞自癒並產生足夠的胰島素來調節血糖值。
轉移性前列腺癌、腎細胞癌、神經膠質瘤和黑色素瘤等幾種腫瘤都是樹突狀細胞癌症疫苗臨床試驗的對象。

全球樹突細胞癌症疫苗市場動態

影響全球樹突細胞癌疫苗市場的關鍵市場動態：

關鍵市場促進因素

癌症發生率不斷上升：癌症已成為全球嚴重的公共衛生問題，每年新增數百萬例癌症病例。癌症發生率的不斷上升，很大程度上推動了諸如樹突狀細胞癌症疫苗等新型有效治療方法的研發。
免疫療法的應用範圍擴大：免疫療法是一種刺激免疫系統對抗癌細胞的癌症治療方法。樹突細胞疫苗是臨床試驗中展現出良好前景的免疫療法。隨著免疫療法的普及，預計對樹突狀細胞癌症疫苗的需求將會增加。
技術進步：技術進步使得更精準、更有效的樹突細胞癌症疫苗成為可能。例如，科學家正在開發分離和刺激樹突狀細胞的新方法，以及如何將樹突細胞疫苗輸送到體內。
增加研發支出：製藥公司和政府機構正在大力投資樹突細胞癌疫苗的研發。預計這項投資將在未來幾年帶來新的、改進的疫苗。

主要挑戰

製造複雜性：樹突狀細胞癌症疫苗的製造過程包括提取患者自身的免疫細胞，在實驗室中進行改造以靶向癌症，然後將免疫細胞重新註入患者體內。疫苗製造過程複雜，成本高且耗時。
療效有限：儘管一些研究顯示出令人鼓舞的結果，但樹突狀細胞癌疫苗已被證明對多種癌症類型不是一種可靠的治療方法。為了提高這些疫苗的有效性，研究人員正在嘗試改進其生產流程。
技術進步樹突細胞癌疫苗市場受到技術進步的推動。個人化疫苗接種和識別最有可能從該治療方法中受益的患者正在受到人工智慧 (AI) 的推動。此外，基因組學能夠識別最佳腫瘤標靶，從而開發更有效的疫苗。人工智慧還可以簡化複雜的生產流程，使其成本更低、更易於取得。技術進步的融合為開發強效的客製化樹突狀細胞癌疫苗打開了大門。

主要趨勢

抗原發現：基因組定序有助於發現腫瘤特異性抗原，即誘導免疫反應的化學物質。人工智慧可以分析和預測這些抗原刺激免疫系統的能力，從而實現更精準的疫苗研發。
腫瘤異質性：即使是同一種癌症的患者，其腫瘤基因組成也會有所不同，這增加了對樹突狀細胞癌症疫苗的需求。
整合專業知識：新興企業通常擁有尖端技術或獨特的抗原靶點，而現有企業則提供生產、監管流程和臨床試驗的知識。整合各方技能可以克服各自的局限性，加速疫苗研發。

Dendritic cells aid the immune system in identifying and eliminating aberrant cells, including cancerous cells. Scientists cultivate dendritic cells alongside cancer cells in the lab in order to create the vaccine. Our immune system is then prompted to combat the malignancy by the vaccine.
In phase II studies, it was demonstrated that dendritic cell immunization might boost the number of lymphocytes invading tumors, trigger an immune response, and improve overall survival for a subset of patients.
A beta-cell protein and the patient's own immune cells, known as dendritic cells, are used to make the vaccine. The vaccination may help the beta-cells heal and produce adequate insulin to regulate blood sugar levels by instructing the immune system to attack on beta-cells.
Multiple tumors, including metastatic prostate cancer, renal cell carcinoma, glioma, and melanoma, have been subjected to a clinical trial of the Dendritic Cell Cancer Vaccination.

Global Dendritic Cell Cancer Vaccine Market Dynamics

The key market dynamics that are shaping the global Dendritic Cell Cancer Vaccine Market include:

Key Market Drivers:

Growing Cancer Prevalence: With millions of new cases reported each year, cancer is a serious public health concern on a global scale. The creation of novel and efficient therapies, such as dendritic cell cancer vaccines, is largely fueled by the rising prevalence of cancer.
Expanding Use of Immunotherapy: Immunotherapy is a cancer treatment that stimulates the immune system to combat cancer cells. One type of immunotherapy that has shown potential in clinical trials is the use of dendritic cell vaccines. Dendritic cell cancer vaccine demand is predicted to increase as immunotherapy gains traction.
Technology Advancements: More precise and potent dendritic cell cancer vaccines are now possible because due to technological advancements. For instance, scientists are creating novel approaches for delivering these vaccinations to the body as well as for isolating and stimulating dendritic cells.
Rising R&D Expenditure: Drug companies and government agencies are making significant investments in the study and creation of vaccines against dendritic cell cancer. In the upcoming years, it is anticipated that this investment will result in the development of new and improved vaccinations.

Key Challenges:

Complexity of Manufacturing: The procedure of creating dendrite cell cancer vaccines is removing a patient's own immune cells, modifying them in a laboratory to target the cancer, and then reintroducing the immune cells to the patient. The production of the vaccinations is costly and time-consuming due to their complication.
Limited Efficacy: Although some research has yielded encouraging results, dendrite cell cancer vaccinations is proving an unreliable treatment for various cancer types. To increase the effectiveness of these vaccinations, researchers are trying to improve their manufacturing process.
Technological Advancements: Dendritic Cell Cancer Vaccine Market is boosting thanks to the technological advancement. Personalized vaccinations and the identification of patients most likely to benefit from this therapy are being facilitated by artificial intelligence (AI). Furthermore, genomics is making it possible to identify the best tumor targets, which will result in vaccines that work better. AI is also simplifying the intricate manufacturing process, which could lower costs and improve accessibility. The convergence of technological developments is opening doors for the development of potent and customized dendritic cell cancer vaccines.

Key Trends:

Antigen Discovery: Genomic sequencing aids in the discovery of tumor-specific antigens, or immunological response-inducing chemicals. The development of more specialized vaccinations will result from AI's analysis and prediction of these antigens' capacity to stimulate the immune system.
Heterogeneity of Tumors: The difference in the genetic makeup of tumors even among patients with the same form of cancer is increasing the demand for dendritic cell cancer vaccine.
Combination of Expertise: While new firms frequently have cutting-edge technologies or distinctive antigen targets, established players provide knowledge in manufacturing, regulatory procedures, and clinical trials. They can overcome individual limits and accelerate the development of vaccines by combining their skills.

Global Dendritic Cell Cancer Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Dendritic Cell Cancer Vaccine Market:

North America:

According to Verified Market Research analyst, North America is expected to hold a major share in the global Dendritic Cell Cancer Vaccine Market. North America has dominated the Dendritic Cell Cancer Vaccine Market mostly due to large-scale research studies funded by pharmaceutical companies and university research institutes, as well as an extraordinary surge in the prevalence of cancer cases.
North American region spend a lot on healthcare, more money may be allocated to the study and creation of cutting-edge cancer treatments, such as dendrite cell cancer vaccinations.
North America has the biggest market share due to increased awareness of cancer treatment and the availability of well-developed healthcare infrastructure and research facilities.
In North America, there is a growing awareness of cancer and accessible treatment choices, which could lead to increasing patient interest in tailored therapies like DC vaccines.

Asia Pacific:

Several countries in Asia-Pacific are actively sponsoring cancer immunotherapy research and development, including DC vaccines. This involves sponsoring programs and reducing regulatory procedures. Countries are developing reimbursement schemes for approved DC vaccines, making them more available to patients.
The evolving healthcare system present encouraging prospects for market growth. Even though the market is still developing in comparison to North America and Europe, a number of domestic and foreign companies are actively engaged in research partnerships and clinical trials. This strong activity suggests that the Asia Pacific area has enormous potential to influence the direction of cancer treatment using dendritic cells.
There is a growing need for new treatment alternatives due to the increased incidence of cancer cases in nations like China and India. A climate that is conducive to the uptake of dendritic cell vaccines is being created by rising public knowledge of immunotherapy and government backing for it.

Global Dendritic Cell Cancer Vaccine Market: Segmentation Analysis

The Global Dendritic Cell Cancer Vaccine Market is segmented on the basis of Product Type, End-User, and Geography.

Dendritic Cell Cancer Vaccine Market, By Product Type

Sipuleucel-T
CreaVax

Based on Product Type, the market is bifurcated into Sipuleucel-T and CreaVax. Sipuleucel-T has the greatest share of the market among the others. The treatment of metastatic prostate cancer in males with sipuleucel-T is clinically authorized. with growing in acceptance. Sipuleucel-T, formerly known as Provenge, is now the market leader for dendritic cell cancer vaccines. This is due to its unique status as the first cancer immunotherapy to receive FDA approval.

Sipuleucel-T is a targeted treatment for men with metastatic castration-resistant prostate cancer who are asymptomatic or very symptomatic. Even though there are currently other dendritic cell vaccines being developed, Sipuleucel-T's established presence and demonstrated efficacy are probably going to help it maintain its market share going forward.

Dendritic Cell Cancer Vaccine Market, By End-User

Pediatric
Adults

Based on End-User, the market is bifurcated into Pediatric and Adults. In the market for cancer vaccines against dendritic cell carcinoma, the adult category is dominant. Numerous factors contribute to this supremacy. First off, adult cancer incidence rates are often higher than those in youngsters. Second, adult malignancies such as lung, breast, and prostate cancers are the focus of a sizable fraction of current clinical trials for dendritic cell vaccines.

The purpose of these trials is to assess the novel medicines' safety and effectiveness in adult patients. Furthermore, well-known competitors in the market, such as the company that created Sipuleucel-T (Provenge), focus mostly on adult patients. Although there is ongoing research into pediatric dendritic cell vaccines, the adult segment currently holds a dominant position in the market due to its established therapeutic choices and state of research.

Key Players

The "Global Dendritic Cell Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, 3M Company, Activartis, Batavia Bioservices, Argos Therapeutics, Sanpower Corporation, Elios Therapeutics, DanDrit Biotech, DCPrime, and ImmunoCellular Therapeutics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Dendritic Cell Cancer Vaccine Market Recent Developments
In September 2021, the development of immunotherapeutic techniques has allowed for the improvement of standard therapies' efficacy in the treatment of oncological disorders. Following the introduction of dendritic cell-based individualized therapeutic vaccines into clinical practice there was no significant advancement. The scope of use for dendritic cell (DC) vaccines has been expanded, and patient indicators for cancer have improved to a clearer understanding of dendritic cell biology and the adoption of novel techniques and agents for antigenic work. Furthermore, encouraging projections of DC vaccines application in broader clinical practice can be used due to their low toxicity in clinical trials.
In June 2021, ASPAGNIITM was being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer. The process begins by extracting monocytes of white blood cell from the patient's blood. These monocytes are then transformed into dendritic cells which act as immune system messengers. The dendritic cells are equipped with a specific protein called ASPAGNIITM. This protein helps them recognize and target cancer cells expressing SPAG9. Finally, after being primed the dendritic cells are reintroduced into the body and there, they guide T cells to identify and destroy the cancer cells.

1 INTRODUCTION OF GLOBAL DENDRITIC CELL CANCER VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, PRODUCT TYPE

5.1 Overview
5.2 Sipuleucel-T
5.3 CreaVax

6 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, END-USER

6.1 Overview
6.2 Pediatric
6.3 Adults

7 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL DENDRITIC CELL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 GlaxoSmithKline plc
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 3M Company
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Activartis
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Batavia Bioservices
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Argos Therapeutics
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Sanpower Corporation
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Elios Therapeutics
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 DanDrit Biotech
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 DCPrime
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 ImmunoCellular Therapeutics
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments